Description for Semglee Semglee contains insulin glargine as a sterile solution for subcutaneous use
Understanding this difference is critical for anyone switching from a brand-name product to a compounded formulation
Pantalone, DO, ECNU, FACE, professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, director of diabetes initiatives and staff endocrinologist in the department of endocrinology at Cleveland Clinic, told Healio | Endocrine Today
24 Months from the Date of Manufacturing
Weight Loss Plateaus Are Normal and Seen in Every Major GLP-1/GIP Study The Standard Weight-Loss Curve Clinical trials consistently show that weight loss with GLP-1 and GLP-1/GIP medications follows a predictable pattern: Rapid weight loss early Gradual slowing over time A plateau phase where weight stabilizes This pattern has been observed across: Semaglutide trials ( STEP program ) Tirzepatide trials ( SURMOUNT-1 , SURMOUNT-4 ) Long-term cardiovascular outcomes studies ( SELECT ) In these studies, most participants lost weight more rapidly during the first several months, then experienced a gradual slowing and reached their average maximum weight loss around 918 months , after which weight tended to stabilize rather than continue to drop indefinitely